"Spring break is on the way, or maybe summer vacation. Time to pack your swim suit, hit the beach, and perhaps indulge in a little harmless fun. What about getting a temporary tattoo to mark the occasion? Who could it hurt to get a temporary tatto"...
Three different formulations were studied during clinical development of Synera (lidocaine and tetracaine) : Developmental A (n=138), Developmental B (n=30), and the Synera (lidocaine and tetracaine) final formulation (n=1281). The developmental patch formulations each contained the same amount of the active drug (70 mg each of lidocaine and tetracaine) as the final patch formulation, but varying amounts of excipients, principally polyvinyl alcohol and water. Data obtained from studies utilizing the developmental patches have been included in the overall evaluation of Synera (lidocaine and tetracaine) safety (calculation of adverse event incidence).
Localized Reactions: During or immediately after treatment with Synera (lidocaine and tetracaine) , the skin at the site of treatment may develop erythema, blanching, edema, or abnormal sensation. In clinical studies involving 1449 Synera (lidocaine and tetracaine) -treated subjects, the most common local reactions were erythema (71%), blanching (12%) and edema (12%). These reactions were generally mild, resolving spontaneously soon after treatment. There were no treatment-related serious adverse events.
Combined, other application site reactions of various types (contact dermatitis, rash, skin discoloration) occurred in less than 4% of Synera (lidocaine and tetracaine) -treated patients during clinical trials. Most were mild, resolving spontaneously soon after patch removal.
Adverse events that each occurred in 1% or less of Synera (lidocaine and tetracaine) -treated subjects included rash, application site reaction, pruritus, dizziness, headache, pain, nausea, contact dermatitis, infection, skin discoloration, somnolence, allergic reaction, blister, paresthesia, urticaria, vesiculobullous rash, and vomiting.
Allergic Reactions: Allergic or anaphylactoid reactions can occur with the active or inactive components of Synera (lidocaine and tetracaine) . They may be characterized by urticaria, angioedema, bronchospasm, and shock. If an allergic reaction occurs, medical management should be by conventional means.
Systemic (Dose-Related) Reactions: Systemic adverse reactions following appropriate use of Synera are unlikely (see CLINICAL PHARMACOLOGY, Pharmacokinetics). Systemic adverse effects of lidocaine and tetracaine are similar in nature to those observed with other amide and ester local anesthetic agents, including CNS excitation and/or depression (light-headedness, nervousness, apprehension, euphoria, confusion, dizziness, drowsiness, tinnitus, blurred or double vision, vomiting, sensations of heat, cold or numbness, twitching, tremors, convulsions, unconsciousness, respiratory depression and arrest). Excitatory CNS reactions may be brief or not occur at all, in which case the first manifestation may be drowsiness merging into unconsciousness. Signs of CNS toxicity may start at plasma concentrations of lidocaine as low as 1000 ng/mL. The plasma concentrations at which tetracaine toxicity may occur are less well characterized; however, systemic toxicity with tetracaine is thought to occur with much lower plasma concentrations compared with lidocaine. The toxicity of co-administered local anesthetics is thought to be at least additive. Cardiovascular manifestations may include bradycardia, hypotension and cardiovascular collapse leading to arrest.
Read the Synera (lidocaine and tetracaine) Side Effects Center for a complete guide to possible side effects
Antiarrhythmic Drugs: Synera (lidocaine and tetracaine) should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the systemic toxic effects are thought to be additive and potentially synergistic with lidocaine and tetracaine.
Local Anesthetics: When Synera (lidocaine and tetracaine) is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations should be considered since the systemic toxic effects are thought to be additive and potentially synergistic with lidocaine and tetracaine.
Read the Synera Drug Interactions Center for a complete guide to possible interactions
Last reviewed on RxList: 1/23/2009
This monograph has been modified to include the generic and brand name in many instances.
Additional Synera Information
- Synera Drug Interactions Center: lidocaine-tetracaine top
- Synera Side Effects Center
- Synera FDA Approved Prescribing Information including Dosage
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.